199915-38-3

Basic information

• Product Name: FMOC ISOTHIOCYANATE
• Synonyms: 9-fluorenylmethoxycarbonyl isothiocyanate;9-Fluorenylmethoxycarbonyl isothiocyanate, 9-Fluorenylmethyl isothiocyanatoformate;O-(9H-fluoren-9-yl)methyl carbonisothiocyanatidate;9H-Fluoren-9-ylmethoxycarbonyl isothiocyanate;Carbon(isothiocyanatidic) acid 9H-fluoren-9-ylmethyl ester;Fmoc isothiocyanate >=98.0% (CHN);9H-fluoren-9-ylmethyl N-(sulfanylidenemethylidene)carbamate;Fmoc-isothiocyanate≥ 95% (NMR)
• CAS NO: 199915-38-3
• Molecular Formula: C₁₆H₁₁NO₂S
• Molecular Weight: 281.33
• Mol File: 199915-38-3.mol
• Article Data: 13

Chemical Properties

• Melting Point: 42-46 °C
• Boiling Point: 433.1°C at 760 mmHg
• Flash Point: 215.7°C
• Appearance: Clear yellow to brown/Liquid
• Density: 1.26
• Vapor Pressure: 1.05E-07mmHg at 25°C
• Refractive Index: 1.653
• Storage Temp.: −20°C
• Solubility: ethanol: soluble
• BRN: 7930648
• CAS DataBase Reference: FMOC ISOTHIOCYANATE(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC ISOTHIOCYANATE(199915-38-3)
• EPA Substance Registry System: FMOC ISOTHIOCYANATE(199915-38-3)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41
• Safety Statements: 36/39
• WGK Germany: 3
• F: 10
• Hazardous Substances Data: 199915-38-3(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow solid

Uses

Fmoc isothiocyanate can be used:As a starting material in the preparation of biologically relevant pharmacophores named N-aryl-N′-carboalkoxy guanidines.In one of the intermediate steps for the synthesis of N-aryl-N-thiazolyl derivatives.To synthesize cyclic isothiourea derivatives as potent neuropeptide Y (NPY) Y1?receptor antagonists.To prepare 2-aminothiazoles, aminobenz-imidazole conjugated thiazoles, and thiazole derived cyclopeptides.

InChI:InChI=1/C16H11NO2S/c18-16(17-10-20)19-9-15-13-7-3-1-5-11(13)12-6-2-4-8-14(12)15/h1-8,15H,9H2

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 333-20-0 potassium thioacyanate 

Downstream Products

• 19735-74-1 4-[(3r,5r,7r-) adamantan-1-yl]thiazol-2-amine 
• 2104-04-3 4-(4-methoxyphenyl)-1,3-thiazol-2-amine 
• 6318-74-7 2-amino-4,5-diphenylthiazole 
• 1027376-20-0 C₂₆H₂₅N₃O₃S 
• 109853-22-7 N-(5-benzylamino-[1,3,4]thiadiazol-2-yl)-2-phenyl-acetamide 
• 109853-21-6 N-(5-benzylamino-[1,3,4]thiadiazol-2-yl)-benzamide 

Relevant articles and documents

Convenient Synthesis of Thiohydantoins, Imidazole-2-thiones and Imidazo[2,1-b]thiazol-4-iums from Polymer-Supported α-Acylamino Ketones

The preparation of 5-methylene-thiohydantoins using solid-phase synthesis is reported in this paper. After sulfonylation of immobilized Ser (t-Bu)-OH with 4-nitrobenzenesulfonyl chloride followed by alkylation with various bromoketones, the 4-Nos group was removed and the resulting polymer-supported α-acylamino ketones reacted with Fmoc-isothiocyanate. Cleavage of the Fmoc protecting group was followed by the spontaneous cyclative cleavage releasing the 5-methylene-thiohydantoin derivatives from the polymer support. Reduction with triethylsilane (TES) yielded the corresponding 5-methyl-thiohydantoins. When Fmoc-isothiocyanate was replaced with alkyl isothiocyanates, the trifluoroacetic acid (TFA) mediated cleavage from the polymer support, which was followed by the cyclization reaction and the imidazo[2,1-b]thiazol-4-iums were obtained. Their conversion in deuterated dimethylsulfoxide led to imidazole-2-thiones.

HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted benzothiazole compounds of Formula (I) or (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS

The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provids compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.